Company intelligence / Profile preview

Encoded Therapeutics

South San Francisco, California, United Statesencoded.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Lead program ETX101 for Dravet syndrome is in clinical trials. ETX201 for Angelman syndrome is in development stage. Programs for chronic pain and Alzheimer's disease are in preclinical development.

Therapeutic areas: Neurology
Modalities: Gene therapyAAV vectorsVectorized miRNA
Industry: Biotech

Drug pipeline

7 assets

etx101

6 more assets in the full pipeline.

Request access →

Partnerships

Prevail Therapeutics (Eli Lilly and Company)

Beyond the preview

Go deeper on Encoded Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Encoded Therapeutics.

Explore the full profile